Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

CK2 inhibitor 2

CK2 inhibitor 2
Contact us for more batch information
Select Batch
Resource Download

CK2 inhibitor 2

Catalog No. T35557Cas No. 2641079-92-5
CK2 Inhibitor 2, characterized as a potent, selective, and orally active inhibitor of CK2, demonstrates an impressive IC50 value of 0.66 nM. It exhibits high selectivity towards Clk2 with an IC50 of 32.69 nM in comparison to CK2. Furthermore, CK2 Inhibitor 2 has been shown to possess promising antiproliferative and antitumor activities [1].
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$98In Stock
5 mg$247In Stock
10 mg$397In Stock
25 mg$788In Stock
50 mg$1,180In Stock
100 mg$1,580In Stock
500 mg$3,180In Stock
1 mL x 10 mM (in DMSO)$272In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "CK2 inhibitor 2"

Product Introduction

Bioactivity
Description
CK2 Inhibitor 2, characterized as a potent, selective, and orally active inhibitor of CK2, demonstrates an impressive IC50 value of 0.66 nM. It exhibits high selectivity towards Clk2 with an IC50 of 32.69 nM in comparison to CK2. Furthermore, CK2 Inhibitor 2 has been shown to possess promising antiproliferative and antitumor activities [1].
In vitro
CK2 inhibitor 2 (compound 1c) effectively inhibits the proliferation of various cancer cell lines including PC-3, HCT-116, MCF-7, HT-29, T24, and LO2, with IC50 values of 4.53 μM, 3.07 μM, 7.50 μM, 5.18 μM, 6.10 μM, and 96.68 μM, respectively. Additionally, it induces apoptosis in HCT-116 cells in a dose-dependent manner with a notable apoptotic ratio of about 55% at 20 μM concentration after 24 hours. It also significantly reduces the expression of phosphorylated Akt1 S129 and Cdc37 S13 in HCT-116 cells, suggesting a mechanism involving the suppression of survival pathways. Furthermore, CK2 inhibitor 2 dose-dependently inhibits ALDH1A1 enzyme activity (IC50 of 0.10 μM) and downregulates its transcription and protein expression in HCT-116 cells, highlighting its potential in targeting cancer-specific metabolic pathways.
In vivo
Administering CK2 inhibitor 2 at doses ranging from 60 to 90 mg/kg orally, twice daily for four weeks, significantly inhibits tumor growth in a dose-dependent manner, achieving a peak inhibition rate of 69% at the 90 mg/kg dosage. A single oral dose of 25 mg/kg in Sprague-Dawley rats reveals pharmacokinetic parameters such as a maximum concentration (C max) of 7017.8 ng/mL, an elimination half-life (t 1/2) of 6.67 hours, and a clearance rate (CL) of 0.60 L/h/kg. The study utilized male BALB/c athymic nude mice, aged 5 weeks and weighing 16-18 grams, injected with HCT-116 cells, demonstrating dose-dependent tumor growth inhibition without noticeable changes in body weight.
Chemical Properties
Molecular Weight392.84
FormulaC21H17ClN4O2
Cas No.2641079-92-5
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 50 mg/mL (127.28 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.5456 mL12.7278 mL25.4557 mL127.2783 mL
5 mM0.5091 mL2.5456 mL5.0911 mL25.4557 mL
10 mM0.2546 mL1.2728 mL2.5456 mL12.7278 mL
20 mM0.1273 mL0.6364 mL1.2728 mL6.3639 mL
50 mM0.0509 mL0.2546 mL0.5091 mL2.5456 mL
100 mM0.0255 mL0.1273 mL0.2546 mL1.2728 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg,each TargetMol | Animal experiments animal weighs 20 g, and the dosage volume is 100 μL. A total of TargetMol | Animal experiments 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL.
Mother liquor preparation method: 2 mg of drug dissolved in 50 μLDMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μLDMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μLTween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.

Keywords